Should the choice of BOIN design parameter p.tox only depend on the target DLT rate?
Fuente:
arXiv
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Preprint |
| Publicado: |
2024
|
| Materias: | |
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1866929277526605824 |
|---|---|
| author | Lu, Rong |
| author_facet | Lu, Rong |
| contents | When the early stopping parameter n.earlystop is relatively small or the cohortsize value is not optimized via simulation, it may be better to use p.tox < 1.4 * target.DLT.rate, or try out different cohort sizes, or increase n.earlystop, whichever is both feasible and provides better operating characteristics. This is because if the cohortsize was not optimized via simulation, even when n.earlystop = 12, the BOIN escalation/de-escalation rules generated using p.tox = 1.4 * target.DLT.rate could be exactly the same as those calculated using p.tox > 3 * target.DLT.rate, which might not be acceptable for some pediatric trials targeting 10% DLT rate. The traditional 3+3 design stops the dose finding process when 3 patients have been treated at the current dose level, 0 DLT has been observed, and the next higher dose has already been eliminated. If additional 3 patients were required to be treated at the current dose in the situation described above, the corresponding boundary table could be generated using BOIN design with target DLT rates ranging from 18% to 29%, p.saf ranging from 8% to 26%, and p.tox ranging from 39% to 99%. To generate the boundary table of this 3+3 design variant, BOIN parameters also need to satisfy a set of conditions. |
| format | Preprint |
| id |
arxiv_https___arxiv_org_abs_2403_09667 |
| institution | arXiv |
| publishDate | 2024 |
| record_format | arxiv |
| spellingShingle | Should the choice of BOIN design parameter p.tox only depend on the target DLT rate? Lu, Rong Medical Physics Methodology When the early stopping parameter n.earlystop is relatively small or the cohortsize value is not optimized via simulation, it may be better to use p.tox < 1.4 * target.DLT.rate, or try out different cohort sizes, or increase n.earlystop, whichever is both feasible and provides better operating characteristics. This is because if the cohortsize was not optimized via simulation, even when n.earlystop = 12, the BOIN escalation/de-escalation rules generated using p.tox = 1.4 * target.DLT.rate could be exactly the same as those calculated using p.tox > 3 * target.DLT.rate, which might not be acceptable for some pediatric trials targeting 10% DLT rate. The traditional 3+3 design stops the dose finding process when 3 patients have been treated at the current dose level, 0 DLT has been observed, and the next higher dose has already been eliminated. If additional 3 patients were required to be treated at the current dose in the situation described above, the corresponding boundary table could be generated using BOIN design with target DLT rates ranging from 18% to 29%, p.saf ranging from 8% to 26%, and p.tox ranging from 39% to 99%. To generate the boundary table of this 3+3 design variant, BOIN parameters also need to satisfy a set of conditions. |
| title | Should the choice of BOIN design parameter p.tox only depend on the target DLT rate? |
| topic | Medical Physics Methodology |
| url | https://arxiv.org/abs/2403.09667 |